These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29673089)

  • 1. Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.
    Huang J; Wang Y; Zhai Y; Wang J
    Thorac Cancer; 2018 Jun; 9(6):745-749. PubMed ID: 29673089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.
    Ding K; Peng Z; Liu D; Xu Y
    J Transl Med; 2024 Aug; 22(1):761. PubMed ID: 39143613
    [No Abstract]   [Full Text] [Related]  

  • 3. [Resistance to anti-EGFR through the successive and cumulative acquisition of two new oncogenic addictions: BRAF and ALK].
    Messekher M; François H; Denis MG; Ferrer-Lopez P; Bost-Bezeaud F; Mazières J; Parrat E
    Rev Mal Respir; 2024 Jun; 41(6):451-454. PubMed ID: 38796386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unfavorable response to capmatinib for MET exon14 skipping after first-line osimertinib in a patient with EGFR-mutated lung adenocarcinoma: A case report and literature review.
    Araki T; Kanda S; Yazaki T; Hirabayashi T; Komatsu M; Sonehara K; Tateishi K; Hanaoka M
    Respir Investig; 2024 Jul; 62(4):677-680. PubMed ID: 38776647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of response to combination treatment with TSA-DC-CTL immunotherapy and osimertinib in EGFR mutated advanced lung adenocarcinoma.
    Han Z; Li T; Zhang H; Liang K; You M; Xu M; Bai F; Zhang T
    Mol Cancer; 2024 Aug; 23(1):163. PubMed ID: 39123231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report.
    Liu J; Xia L; Peng Y; Huang YS; Yang ZZ
    Medicine (Baltimore); 2021 Oct; 100(39):e27289. PubMed ID: 34596125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of Ph
    Zhang Q; Zhou JD; Ding H; Yang L; Lu C; Chu MQ; Qian J; Zhang TJ
    BMC Med Genomics; 2024 Jul; 17(1):182. PubMed ID: 38978091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response
    Foggetti G; Li C; Cai H; Hellyer JA; Lin WY; Ayeni D; Hastings K; Choi J; Wurtz A; Andrejka L; Maghini DG; Rashleigh N; Levy S; Homer R; Gettinger SN; Diehn M; Wakelee HA; Petrov DA; Winslow MM; Politi K
    Cancer Discov; 2021 Jul; 11(7):1736-1753. PubMed ID: 33707235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer.
    Wang Y; Hu C; Yu H; Hu J; Zhou Z; Fu N; Huang X; Kong F; Wang W; Liu J
    Lung Cancer; 2024 Mar; 189():107495. PubMed ID: 38335691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The disappearance of gastric metastasis and liver metastasis in non-small cell lung adenocarcinoma is due to osimertinib.
    Wang Y; Yan C; Zhang C; Yu E; Wang K; Liu X; Yu J; Zhou C; Yang A
    J Cancer Res Clin Oncol; 2023 Nov; 149(17):16069-16073. PubMed ID: 37695388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.
    Hobor S; Al Bakir M; Hiley CT; Skrzypski M; Frankell AM; Bakker B; Watkins TBK; Markovets A; Dry JR; Brown AP; van der Aart J; van den Bos H; Spierings D; Oukrif D; Novelli M; Chakrabarti T; Rabinowitz AH; Ait Hassou L; Litière S; Kerr DL; Tan L; Kelly G; Moore DA; Renshaw MJ; Venkatesan S; Hill W; Huebner A; Martínez-Ruiz C; Black JRM; Wu W; Angelova M; McGranahan N; Downward J; Chmielecki J; Barrett C; Litchfield K; Chew SK; Blakely CM; de Bruin EC; Foijer F; Vousden KH; Bivona TG; ; Hynds RE; Kanu N; Zaccaria S; Grönroos E; Swanton C
    Nat Commun; 2024 Jun; 15(1):4871. PubMed ID: 38871738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design of non-resistant targeted cancer therapies.
    Martínez-Jiménez F; Overington JP; Al-Lazikani B; Marti-Renom MA
    Sci Rep; 2017 Apr; 7():46632. PubMed ID: 28436422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenocarcinoma Harboring
    Lai SY; Richardson NH; Tran M; Hanna NH; Shields MD
    JTO Clin Res Rep; 2024 Apr; 5(4):100652. PubMed ID: 38525318
    [No Abstract]   [Full Text] [Related]  

  • 14. Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases.
    Schapira E; Hubbeling H; Yeap BY; Mehan WA; Shaw AT; Oh K; Gainor JF; Shih HA
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):624-629. PubMed ID: 29678530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.
    Masuda K; Tokito T; Azuma K; Yanagida E; Nakamura M; Naito Y; Matsuo N; Ishii H; Yamada K; Akiba J; Hoshino T
    Thorac Cancer; 2018 Jun; 9(6):754-757. PubMed ID: 29675860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
    Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T
    Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.
    Uchibori K; Inase N; Nishio M; Fujita N; Katayama R
    J Thorac Oncol; 2018 Jul; 13(7):915-925. PubMed ID: 29702287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.
    Bisagni A; Pagano M; Maramotti S; Zanelli F; Bonacini M; Tagliavini E; Braglia L; Paci M; Mozzarelli A; Croci S
    PLoS One; 2018; 13(4):e0196350. PubMed ID: 29689091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.
    Claret L; Jin JY; Ferté C; Winter H; Girish S; Stroh M; He P; Ballinger M; Sandler A; Joshi A; Rittmeyer A; Gandara D; Soria JC; Bruno R
    Clin Cancer Res; 2018 Jul; 24(14):3292-3298. PubMed ID: 29685883
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.